Scott M. Rocklage

Founding Partner at 5AM Ventures

Scott M. Rocklage, PhD joined 5AM Ventures in 2003 as a Venture Partner, became a Managing Partner in 2004 and transitioned to Founding Partner in 2017. Dr. Rocklage has over three decades of healthcare management experience with strategic leadership responsibilities that led to FDA approval of three U.S. New Drug Applications (Omniscan™, Teslascan® and Cubicin®). He has served as Chairman and CEO of Cubist Pharmaceuticals, President and CEO of Nycomed Salutar and has also held R&D positions at Salutar and Catalytica. Dr. Rocklage formerly served as Board Chairman of Relypsa (acquired by Vifor Pharma), Novira (acquired by J&J), Aprea (NASDAQ: APRE) and Cidara (NASDAQ: CDTX). He currently serves as Board Chairman of Albamunity, Expansion, Kinestral and is a Board member at NodThera and Nouscom. He was formerly Executive Chairman of Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed) and Semprus (acquired by Teleflex). Dr. Rocklage received his B.S. in Chemistry from the University of California, Berkeley and his Ph.D. in Chemistry from MIT where he conducted research in the laboratory of Richard R. Schrock (Nobel Prize in Chemistry in 2005). He is an inventor or co-inventor of over 35 U.S. patents and has produced more than 100 peer-reviewed publications. Dr. Rocklage is based in the Boston, MA office.

Location

Palm Beach Gardens, United States

Links


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


5AM Ventures

2 followers

5AM was founded in 2002 and pursues investments in advanced life science innovations, and seeks to be diversified across the biopharmaceutical therapeutics, and platform technologies.


Industries

Employees

11-50

Links